RecruitingNCT07414056

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation


Sponsor

Ain Shams University

Enrollment

60 participants

Start Date

Nov 10, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study is to evaluate the role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as predictors for development of ARDS in pediatric burn patients.


Eligibility

Min Age: 1 YearMax Age: 12 Years

Inclusion Criteria5

  • Age 1-12 years.
  • Patients presenting within 24 hours of burn injury.
  • Patients presenting with severe burns 20-40% of total body surface area (TBSA).
  • Thermal burns or scalds.
  • Both sexes.

Exclusion Criteria12

  • Patient refusal to participate in the trial.
  • Age \<1 \& \>12 years.
  • Delayed admission \>24h post-injury.
  • Patients presenting with burns \<20% or \>40% of TBSA.
  • Non-thermal burns.
  • Associated medical comorbidities: Chronic liver or kidney diseases, anemia.
  • Preexisting chronic lung disease (e.g., cystic fibrosis, severe bronchopulmonary dysplasia).
  • Inflammatory conditions (e.g., inflammatory bowel disease).
  • Immunocompromised individuals, autoimmune diseases, those undergoing treatment with immunosuppressants, corticosteroids, cytotoxic chemotherapy.
  • Known malignancies, hematologic malignancy or conditions altering WBC/platelets significantly.
  • Previous malnutrition.
  • Immunosuppressive therapy prior to admission (e.g., chronic steroids).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTNeutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients


Locations(1)

Ain Shams University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07414056


Related Trials